Effects of Different Continuous Renal Replacement Therapy Patterns on Ionized Calcium in Patients With Citrate Anticoagulants Using Calcium-containing Replacement Solutions

Last updated: March 10, 2025
Sponsor: Fujian Provincial Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Renal Failure

Hemodialysis

Treatment

CVVHD

CVVH

Clinical Study ID

NCT06021080
HChen
  • Ages 18-100
  • All Genders

Study Summary

It is unclear whether different modes of continuous renal replacement therapy (CRRT) impact post-filter ionized calcium concentrations during regional citrate anticoagulation (RCA) when using calcium-containing replacement fluid.

This prospective, single-center, observational cohort study will screen all patients receiving CRRT for eligibility. General clinical information will be collected before commencing CRRT treatment. Patients will be randomly assigned to either the veno-venous hemofiltration (CVVH) or continuous veno-venous hemodialysis (CVVHD) group and switch to the alternative mode in the subsequent treatment session. Pre-filter and post-filter ionized calcium, systemic total and ionized calcium, and effluent total and ionized calcium will be measured 2 hours after the initiation of CRRT. Electrolyte levels, arterial blood gases, hourly citrate dose, and total citrate dose will be recorded every 6 hours until the end of CRRT. The primary outcome is the difference in ionized calcium concentrations at each site over time between the two modes.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥ 18 years old;

  2. Receiving citrate anticoagulation;

  3. Obtain Informed consent from patients or next of kin.

Exclusion

Exclusion Criteria:

  1. Pregnant or lactating women;

  2. Allergic to citrate anticoagulants;

  3. Severe liver dysfunction (total bilirubin levels exceeding two times the normalrange);

  4. Hypoxemia (PaO2 < 60 mmHg);

  5. Inadequate tissue perfusion (blood pressure < 90/60 mmHg despite high doses ofvasoactive agents);

  6. Hyperlactatemia (lactate> 4 mmol/L);

  7. Hypernatremia;

  8. Estimated length of hospital stay < 48h;

  9. Participated in other studies.

Study Design

Total Participants: 30
Treatment Group(s): 2
Primary Treatment: CVVHD
Phase:
Study Start date:
October 09, 2023
Estimated Completion Date:
December 09, 2025

Connect with a study center

  • Fujian Provincial Hospital

    Fuzhou, Fujian 350001
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.